CryoCath down under
This article was originally published in The Gray Sheet
Executive Summary
Montreal firm announces March 26 the introduction at two centers in Australia of its Arctic Front cryoablation balloon catheter for the treatment of paroxysmal, or episodic, atrial fibrillation. The device is already being used at 34 centers in Europe. CryoCath says it is on track to complete enrollment in its STOP AF pivotal U.S. trial in April, and anticipates a late 2009 PMA approval